The Roche Innovation Center Zurich functions as a Center of Excellence for Oncology within Roche Pharma Research and Early Development (pRED), with a primary focus on Cancer Immunotherapy. The center is renowned for its expertise in advancing innovative research in this field. By integrating Pharmaceutical Science and Data & Analytics, in collaboration with Discovery and Early Development Oncology, the center aims to create transformative medicines.
Glycart Biotechnology AG was initially established in September 2000 as a spin-off of the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland. In the summer of 2005, it was acquired by the Roche Group and integrated into Roche Pharma Research and Early Development (pRED).
The state of the art research complex based in Schlieren, Switzerland, is now an integral part of Roche Pharma Research and Early Development. Roche Innovation Center Zurich is one of five Roche Pharma Research and Early Development Innovation Centers. It boasts a multinational team of research scientists – with a dynamic, thriving biotech culture. Roche Innovation Center Zurich comprises research teams focussing on discovering and developing step-change innovations in cancer immunotherapy and cancer cell targeted therapy. The teams belong to the oncology DTA Discovery, Early Development Oncology and global functions including Pharmaceutical Sciences, Data & Analytics, and Operations. Roche Innovation Center Zurich additionally hosts a satellite team from the Institute of Human Biology dedicated to research in organoids, human model systems and translational bioengineering.
Roche Innovation Center Zurich focuses on product development – from scientific concepts and validation to the corresponding studies. Today the compounds studied and developed are boosting Roche’s significant commitment towards offering improved cancer medicines.